REPEAT: AstraZeneca, Amlin Get Positive Results From Phase 3 Brodalumab Study For Psoriasis
LONDON (Alliance News) - AstraZeneca PLC and Amgen Inc said Monday that the Phase 3 AMAGINE-1 study evaluating brodalumab in patients with moderate-to-severe plaque psoriasis met all primary and secondary endpoints for both evaluated doses. Brodalumab is the only investigational treatment i Read More